Salbutamol: tablets, inhalational powder, or nebuliser?

K GRIMWOOD, J J JOHNSON-BARRETT, BRENT TAYLOR

Abstract

A study was carried out to ascertain the most effective method of giving salbutamol. Seventeen children with severe asthma received active salbutamol (4 mg via a nebuliser, 400 μg as an inhalational powder, or a 4 mg tablet) together with complementary placebos on a double-blind, triple-dummy randomly allocated basis. The bronchodilatation effect was assessed by measuring the peak expiratory flow rate.

The bronchodilatation effect was greatest when patients received nebulised salbutamol (p < 0.05) but lasted longest when they received the tablet (p < 0.0001); the onset of the effect was rapid with all forms of administration.

These results indicate that nebulised salbutamol gives the best relief in severe asthma; in less severe cases, however, a regimen combining the inhalational powder and tablets is sufficient and more convenient.

Introduction

Salbutamol has been used to treat asthma for about 15 years. Oral forms are generally believed to be less effective than inhaled forms, but few data exist to support this belief. A recent trial in asthmatic pre-school children showed an enhanced bronchodilator effect when nebulised salbutamol was given 90 minutes after an oral dose, but no direct comparisons were made.

Metered-dose aerosols are not without problems; despite careful tuition they are used ineffectively by 14% of adults,2 and the active drug or propellant may cause adverse effects,3,4 and the aerosols may be overused, especially in adolescence.4 Children aged under 5 years can seldom use a metered aerosol at all, and most of those under 8-10 years cannot use an aerosol effectively during an acute episode of wheezing.7

Salbutamol delivered as a nebulised solution is effective in reducing bronchospasm in children aged over 20 months.8 Oral salbutamol and powdered salbutamol inhaled from a Rotahaler are effective in children aged over 3.9 10 salbutamol as an inhalational powder is at least as good as that given by metered aerosol in children aged over 7.8 The bronchodilator effect of fenoterol in powder form is stronger and lasts longer than that of the same dose given by metered aerosol.11

In this study we compared three different modes of administration of salbutamol—namely, tablets, inhalational powder, and nebuliser.

Subjects and methods

We studied 17 children (seven boys and 10 girls) aged 4-12 (mean 7.2) years. The mean duration of asthmatic symptoms was 4-9 years (range one to 10 years). All had severe recurrent or chronic asthma (grade C or D)8 and were receiving continuous treatment with bronchodilators by mouth or inhalation, or both, and prophylactic anti-asthma treatment.

<table>
<thead>
<tr>
<th>Time after administration</th>
<th>Baseline</th>
<th>15 min</th>
<th>45 min</th>
<th>90 min</th>
<th>4 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tablet</td>
<td>58</td>
<td>98</td>
<td>91</td>
<td>97</td>
<td>85</td>
</tr>
<tr>
<td>Rotahaler</td>
<td>60</td>
<td>98</td>
<td>98</td>
<td>99</td>
<td>63</td>
</tr>
<tr>
<td>Nebuliser</td>
<td>59</td>
<td>101</td>
<td>107</td>
<td>107</td>
<td>75</td>
</tr>
</tbody>
</table>

Mean peak expiratory flow rate expressed as percentage of that expected and as percentage improvement over baseline values in 17 severely asthmatic children given salbutamol by mouth, Rotahaler, and nebuliser
analysis of variance with the three variables (treatments) over the four times shown in the table showed a significant difference in drug effect (0.05 > p > 0.01), trial effect (p < 0.001), and drug-trial interaction (p < 0.0001). The bronchodilatation effect was greater with nebulised salbutamol compared with the two other forms of administration but lasted longer with the oral treatment. Improvement in peak expiratory flow rate occurred rapidly after administration with all three methods. At 15 minutes the improvements in peak expiratory flow rate over baseline values achieved with the tablet and the powder were 61% and 75% respectively of the improvement achieved with the nebuliser.

Discussion

This study shows that the maximal bronchodilatation effect is obtained with nebulised salbutamol and confirms the effectiveness of this form of administration in asthmatic children. Unfortunately, nebulising systems are cumbersome and expensive and should probably be reserved for severely asthmatic patients.

The powder and tablet are easily administered and have a rapid onset of action. The powder is effective from at least the age of 3, and inhaled forms reliably block exercise-induced bronchoconstriction. Our study showed that the effect obtained with the powder was comparatively short, suggesting a need for frequent (three-hourly) administration. An increased dose might give a longer action. Powder forms are at least as good or better than metered-dose aerosols and avoid the risks, theoretical or otherwise, of using the aerosols.

The oral form, which is effective from at least the age of 3, had a surprisingly rapid onset of action, and its bronchodilatation effect was superior to that of most of the other forms of administration after four and six hours. It is less effective in exercise-induced bronchoconstriction, but its longer-lasting action has implications for prominent nocturnal symptoms. A combination of oral and inhaled forms has an additive effect on bronchodilatation with minimal increase in side effects; such combination treatment in childhood needs further evaluation. All the children in this study had been taking oral or nebulised salbutamol regularly for months or years, which might explain the absence of troublesome side effects apparently prevalent in adults taking large doses; children generally tolerate sympathomimetics well.

A regimen in which the powder is given during the day while the patient is active and the oral form given last thing at night or as baseline treatment may thus be optimal sympathomimetic treatment. Nebulised salbutamol should be reserved for patients with severe asthma.

We thank Mrs. Catherine Reay for helping with this study; and Allen and Hanburys, division of Glaxo Laboratories (NZ) Ltd for providing placebo tablets and capsules.

References


(Accepted 31 October 1980)

SHORT REPORTS

Hospital admissions for whooping cough in the Oxford Region, 1974-9

The number of statutory notifications for whooping cough in the United Kingdom increased substantially during 1977-9 compared with the previous few years. There has been speculation (a) about the extent to which this represented an increase in the proportion of cases notified as well as an increase in the incidence of the disease; (b) about the extent to which other respiratory illnesses may have been misdiagnosed and notified erroneously as whooping cough; and (c), because the increase in notification has not been paralleled by an increase in deaths from whooping cough, about whether any real increase in incidence has been one of relatively mild cases. We therefore studied statistics on hospital care for whooping cough in the Oxford Region.

Methods and results

Data on hospital discharges in the Oxford Region were obtained from Hospital Activity Analysis. This covers six of the seven health districts in the region (total population of districts covered about 2 million). The existence of linkable hospital data in the Oxford Region enabled us to identify a few patients who were readmitted to or transferred between hospitals, and to exclude their second and subsequent hospital episodes from the results. The diagnosis in Hospital Activity Analysis is that given at the time of the patients' discharge from hospital, but, for comparison with notifications, the data were analysed according to the dates of admission. Notification statistics for whooping cough were obtained for patients resident in the same six districts.

The figure shows the number of hospital admissions and statutory notifications in the six districts, plotted logarithmically, in each quarter of the year from 1974 to 1979 inclusive. The size of the population in the relevant age groups did not vary appreciably during the period and the results for age-specific admission rates were similar to those shown in the figure. The number of hospital admissions in the quarters centred on the 1978 peak was significantly higher than that in the quarters centred on the 1974 peak (Wilcoxon's rank sum test: p<0.05). Analysis by calculation of the correlation coefficient on the logarithmically transformed data showed a statistically significant association between the quarterly number of notifica-